NCT07521202Recruiting
IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE
A Scientific Study Evaluating Therapy Persistence in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer Under Adjuvant Treatment With Abemaciclib Who Receive Standardized Patient Education and Counselling.
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
The goal of this interventional study is to evaluate the effect of standardized patient coaching on treatment adherence among patients taking abemaciclib. The main question it aims to answer is, whether standardized coaching leads to patients taking abemaciclib much more consistently. Researchers will therefore compare therapy adherence of patients receiving standardized coaching to patients receiving routine care. Participants will be asked to answer several questionnaires.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 257 (estimated)
- First submitted
- 27 Mar 2026
- Start date
- 19 Jun 2026
- Primary completion date
- Jun 2029
- Lead sponsor
- Institut fuer Frauengesundheit
- Diseases
- Childhood cancers
- NCT number
- NCT07521202
What you commit to
- Study type: Interventional
- Planned participants: 257
- From 19 Jun 2026 to the primary completion date, Jun 2029
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Women who are pregnant or lactating
- Patients with contraindications against abemaciclib according to the current SmPC
- Patients who are not eligible for the study due to severe comorbidities, unavailability or any other relevant reason according to the treating physician
Who the study is looking for
- Women age 18 or older at time of ICF signature
- Patients with HRpos/HER2neg early breast cancer who are treated with oral, commercially available prescribed abemaciclib in combination with endocrine therapy. Patients can be included if abemaciclib therapy was started no more than 28 days ago
- Patients treated with abemaciclib according to the SmPC and each center´s medical practice
- Informed consent given prior to the starting study activities
Sex: Female · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MVZ am Klinikum Aschaffenburg GmbH Coordinator of this site? Confirm its status | Aschaffenburg | Germany | Recruiting |
| Evangelisches Klinikum Bergisch Gladbach, Gynäkologie Coordinator of this site? Confirm its status | Bergisch Gladbach | Germany | Recruiting |
| Department of Obstetrics and Gynaecology Coordinator of this site? Confirm its status | Erlangen | Germany | Recruiting |
| Klinikum Esslingen, Frauenheilkunde und Geburtshilfe Coordinator of this site? Confirm its status | Esslingen am Neckar | Germany | Recruiting |
| Klinikum Itzehoe, Holsteinisches Brustzentrum Coordinator of this site? Confirm its status | Itzehoe | Germany | Recruiting |
| Klinikum Kulmbach, Brustzentrum Coordinator of this site? Confirm its status | Kulmbach | Germany | Recruiting |
| Universitätsklinikum Schleswig-Holstein, Klinik für Frauenheilkunde und Geburtshilfe (Gynäkologie) Coordinator of this site? Confirm its status | Lübeck | Germany | Recruiting |
| MVZ für Onkologie und Urologie GmbH Coordinator of this site? Confirm its status | Wilhelmshaven | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.